S&P 500   3,916.64
DOW   31,861.98
QQQ   305.80
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
Modern Day Options Trading For Beginners! (Ad)pixel
Niinistö: Sweden security OK if Finland joins NATO first
Which Gold Stocks Can Help You Hedge Bank Exposure?
Modern Day Options Trading For Beginners! (Ad)pixel
The End of Coca Cola's Compressed Margins
Enphase Energy is Still a Buy for Long-Term Growth Investors
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.80
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
Modern Day Options Trading For Beginners! (Ad)pixel
Niinistö: Sweden security OK if Finland joins NATO first
Which Gold Stocks Can Help You Hedge Bank Exposure?
Modern Day Options Trading For Beginners! (Ad)pixel
The End of Coca Cola's Compressed Margins
Enphase Energy is Still a Buy for Long-Term Growth Investors
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.80
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
Modern Day Options Trading For Beginners! (Ad)pixel
Niinistö: Sweden security OK if Finland joins NATO first
Which Gold Stocks Can Help You Hedge Bank Exposure?
Modern Day Options Trading For Beginners! (Ad)pixel
The End of Coca Cola's Compressed Margins
Enphase Energy is Still a Buy for Long-Term Growth Investors
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.80
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Forbes mag says this strategy "like finding money in the street" (Ad)pixel
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
Modern Day Options Trading For Beginners! (Ad)pixel
Niinistö: Sweden security OK if Finland joins NATO first
Which Gold Stocks Can Help You Hedge Bank Exposure?
Modern Day Options Trading For Beginners! (Ad)pixel
The End of Coca Cola's Compressed Margins
Enphase Energy is Still a Buy for Long-Term Growth Investors
NASDAQ:ABOS

Acumen Pharmaceuticals - ABOS Stock Forecast, Price & News

$3.87
-0.14 (-3.49%)
(As of 03/17/2023 06:55 PM ET)
Add
Compare
Today's Range
$3.85
$4.09
50-Day Range
$3.87
$6.65
52-Week Range
$3.02
$10.97
Volume
127,400 shs
Average Volume
81,902 shs
Market Capitalization
$156.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.67

Acumen Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
356.5% Upside
$17.67 Price Target
Short Interest
Bearish
2.29% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.75mentions of Acumen Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.01) to ($1.38) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

543rd out of 983 stocks

Biological Products, Except Diagnostic Industry

98th out of 161 stocks


ABOS stock logo

About Acumen Pharmaceuticals (NASDAQ:ABOS) Stock

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Receive ABOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acumen Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ABOS Stock News Headlines

Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
ABOS Acumen Pharmaceuticals, Inc.
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
Short Volatility Alert: Acumen Pharmaceutical
Earnings Preview: Acumen Pharmaceuticals
See More Headlines
Receive ABOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acumen Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ABOS Company Calendar

Last Earnings
11/14/2021
Today
3/20/2023
Next Earnings (Estimated)
3/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABOS
Fax
N/A
Employees
14
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.67
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+356.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-100,610,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.44 million
Book Value
$5.56 per share

Miscellaneous

Free Float
38,599,000
Market Cap
$156.74 million
Optionable
Not Optionable
Beta
-1.48

Key Executives

  • Mr. Daniel J. O'Connell M.B.A. (Age 52)
    CEO, Pres & Director
    Comp: $801.62k
  • Mr. Matt Zuga
    CFO, Chief Bus. Officer & Corp. Sec.
  • Dr. Eric Siemers M.D. (Age 68)
    Chief Medical Officer
    Comp: $460.64k
  • Mr. Russell Barton M.S. (Age 64)
    Chief Operating Officer
  • Mr. Derek M. Meisner Esq. (Age 52)
    J.D., Chief Legal Officer
  • Ms. Robyn Moxon M.A.
    Mang. of Corp. & Clinical Communications
  • Ms. Julie Bockenstette
    Exec. VP & Head of HR
  • Ms. Siew Tin Gan M.S.
    Assistant VP & Head of Clinical Operations
  • Ms. Janice Hitchcock
    VP & Head of Regulatory Affairs
  • Ms. Liean Schenck M.S.
    VP & Head of CMC













ABOS Stock - Frequently Asked Questions

Should I buy or sell Acumen Pharmaceuticals stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acumen Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ABOS shares.
View ABOS analyst ratings
or view top-rated stocks.

What is Acumen Pharmaceuticals' stock price forecast for 2023?

3 analysts have issued 1 year target prices for Acumen Pharmaceuticals' stock. Their ABOS share price forecasts range from $15.00 to $22.00. On average, they expect the company's stock price to reach $17.67 in the next twelve months. This suggests a possible upside of 356.5% from the stock's current price.
View analysts price targets for ABOS
or view top-rated stocks among Wall Street analysts.

How have ABOS shares performed in 2023?

Acumen Pharmaceuticals' stock was trading at $5.40 at the beginning of 2023. Since then, ABOS shares have decreased by 28.3% and is now trading at $3.87.
View the best growth stocks for 2023 here
.

Are investors shorting Acumen Pharmaceuticals?

Acumen Pharmaceuticals saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 634,100 shares, an increase of 6.2% from the February 13th total of 597,000 shares. Based on an average trading volume of 81,300 shares, the short-interest ratio is currently 7.8 days. Approximately 2.3% of the shares of the stock are short sold.
View Acumen Pharmaceuticals' Short Interest
.

When is Acumen Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our ABOS earnings forecast
.

How were Acumen Pharmaceuticals' earnings last quarter?

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) posted its quarterly earnings data on Sunday, November, 14th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.07.

When did Acumen Pharmaceuticals IPO?

(ABOS) raised $125 million in an IPO on Thursday, July 1st 2021. The company issued 8,333,333 shares at $14.00-$16.00 per share.

What is Acumen Pharmaceuticals' stock symbol?

Acumen Pharmaceuticals trades on the NASDAQ under the ticker symbol "ABOS."

Who are Acumen Pharmaceuticals' major shareholders?

Acumen Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (1.64%), Driehaus Capital Management LLC (1.39%), Pathstone Family Office LLC (1.31%), Silverarc Capital Management LLC (0.73%), Geode Capital Management LLC (0.41%) and WMS Partners LLC (0.24%). Insiders that own company stock include John A Stalfort III, Marc Benioff, Nathan B Fountain, Paul B Manning and Sands Capital Global Venture F.
View institutional ownership trends
.

How do I buy shares of Acumen Pharmaceuticals?

Shares of ABOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acumen Pharmaceuticals' stock price today?

One share of ABOS stock can currently be purchased for approximately $3.87.

How much money does Acumen Pharmaceuticals make?

Acumen Pharmaceuticals (NASDAQ:ABOS) has a market capitalization of $156.74 million and generates $1.44 million in revenue each year.

How can I contact Acumen Pharmaceuticals?

The official website for the company is www.acumenpharm.com. The company can be reached via phone at 434-297-1000 or via email at investors@acumenpharm.com.

This page (NASDAQ:ABOS) was last updated on 3/20/2023 by MarketBeat.com Staff